{"organizations": [], "uuid": "78badcb91422649b04ef39ce8a29582dc0be12d7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/07/22/astrazeneca-melanoma-idUSL5N1020RL20150722", "country": "US", "title": "AstraZeneca drug selumetinib fails in uveal melanoma trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "AstraZeneca drug selumetinib fails in uveal melanoma trial | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-07-22T10:27:00.000+03:00", "replies_count": 0, "uuid": "78badcb91422649b04ef39ce8a29582dc0be12d7"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/07/22/astrazeneca-melanoma-idUSL5N1020RL20150722", "ord_in_thread": 0, "title": "AstraZeneca drug selumetinib fails in uveal melanoma trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, July 22 AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal melanoma.\nThe drugmaker said the setback would not affect other studies using the drug. Selumetinib is being investigated primarily as a treatment for advanced non-small cell lung cancer. (Reporting by Ben Hirschler , editing; by Louise Heavens)", "external_links": [], "published": "2015-07-22T10:27:00.000+03:00", "crawled": "2015-07-22T09:38:19.125+03:00", "highlightTitle": ""}